
If you have any other questions, please contact our experts.
TAK-500 is a first-in-class antibody-drug conjugate (ADC) that delivers the STING agonist dazostinag selectively to CCR2 immune cells for immuno-oncology applications. The key challenge was conjugating the cyclic dinucleotide (CDN) payload, which lacks conventional conjugation handles and is highly hydrophilic.
The authors introduced a self-immolative spacer between the adenine and the Z-Val-Ala-OH-derived cathepsin B-cleavable dipeptide. This design ensured plasma stability while enabling rapid payload release upon lysosomal internalization. The optimized linker-payload 9 was conjugated stochastically to a CCR2-targeting antibody via cysteine maleimide chemistry, yielding TAK-500 with an average drug-to-antibody ratio (DAR) of 4.
Fig. 1 Self-immolation of spacers attached to the Nitrogen on the Nucleobase. (Lee H M.; et al. 2025)
References
Cat NO.: INT1352882804
CAS NO.: 1352882-80-4
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
